Guggenheim Capital’s Astria Therapeutics ATXS Stock Holding History

Guggenheim Capital’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,727	Closed	-$140K	–	1615
2025 Q4	$140K	Buy	+10,727	New	+$128K	﹤0.01%	1712

Guggenheim Capital's ATXS Position: Q1 2026 in Review

Guggenheim Capital sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 10,727 shares — an estimated $140K sold.

Guggenheim Capital first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $140K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Guggenheim Capital reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Guggenheim Capital sold 10,727 Astria Therapeutics shares in Q1 2026, an estimated $140K.
Guggenheim Capital first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Guggenheim Capital's Astria Therapeutics position peaked at $140K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.